PUBLISHER: The Business Research Company | PRODUCT CODE: 1957615
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957615
Pharma grade cellulose powder is a purified, plant-derived material manufactured to meet strict pharmaceutical quality standards. It is widely used as an excipient in drug formulations. Its chemically inert, non-toxic, and stable nature ensures compatibility with active pharmaceutical ingredients (APIs) and improves the uniformity and production efficiency of oral solid dosage forms.
The main types of pharma grade cellulose powder include microcrystalline cellulose (MCC), carboxymethyl cellulose (CMC), hydroxypropyl methylcellulose (HPMC), and hydroxypropyl cellulose (HPC). Microcrystalline cellulose (MCC) is a stable, compressible derivative of wood pulp extensively used in pharmaceuticals as a binder, filler, and disintegrant due to its excellent flow and direct compression properties. It serves multiple functions such as a binding agent, thickener, stabilizer, disintegrant, and coating agent across applications including pharmaceuticals, nutraceuticals, cosmetics, and others. It is utilized by a range of end users, including contract research organizations (CROs), pharmaceutical and biotechnology companies, academic and research institutions, dietary supplement manufacturers, and the food and beverage industry.
Tariffs have impacted the pharma grade cellulose powder market by increasing the cost of imported raw cellulose and specialized processing equipment used in excipient production. These impacts are most pronounced in pharmaceutical and nutraceutical manufacturing regions across North America, Europe, and Asia Pacific, where excipient supply chains are globally integrated. Rising tariff related expenses have contributed to higher excipient prices and margin pressure for manufacturers. This has influenced procurement strategies and formulation cost structures for drug and supplement producers. However, tariffs have promoted regional sourcing, localized excipient processing, and stronger long term supply chain resilience.
The pharma grade cellulose powder market research report is one of a series of new reports from The Business Research Company that provides pharma grade cellulose powder market statistics, including pharma grade cellulose powder industry global market size, regional shares, competitors with a pharma grade cellulose powder market share, detailed pharma grade cellulose powder market segments, market trends and opportunities, and any further data you may need to thrive in the pharma grade cellulose powder industry. This pharma grade cellulose powder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharma grade cellulose powder market size has grown strongly in recent years. It will grow from $1.55 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to growth in oral drug formulations, widespread use of cellulose excipients, expansion of pharmaceutical manufacturing, demand for formulation stability, regulatory acceptance of cellulose-based excipients.
The pharma grade cellulose powder market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growth in nutraceutical applications, rising demand for clean-label excipients, expansion of generic drug pipelines, advancements in excipient engineering, increasing sustainability requirements. Major trends in the forecast period include rising demand for plant-based pharmaceutical excipients, increasing use in solid oral dosage forms, growing adoption of microcrystalline cellulose, expansion of multi-functional cellulose excipients, increasing focus on sustainable excipient sourcing.
The increasing pharmaceutical production is expected to drive the growth of the pharma-grade cellulose powder market in the coming years. Pharmaceutical production involves the formulation, synthesis, and quality control of active ingredients and excipients to ensure medicines are safe, effective, and compliant with regulatory standards. The rise in chronic diseases, which require long-term and continuous medication, is contributing to the growth of pharmaceutical production. Pharma-grade cellulose powder supports this production by acting as a reliable binder, filler, and stabilizer, maintaining tablet integrity and ensuring uniform drug distribution. For example, in June 2023, data from the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the European pharmaceutical industry, reported that total pharmaceutical production in Europe reached $422,803 million (€390,000 million) in 2023, up from $393,857 million (€363,300 million) in 2022. Consequently, the rising pharmaceutical production is boosting the growth of the pharma-grade cellulose powder market.
Major companies operating in the pharma-grade cellulose powder market are focusing on developing new microcrystalline cellulose (MCC) facilities to expand production capacity and strengthen supply chain capabilities for pharmaceutical excipients. An MCC facility is a specialized plant where purified cellulose undergoes controlled chemical and mechanical processes to produce uniform, fine-grade particles for pharmaceutical applications. For instance, in September 2023, Nitika Pharmaceuticals Specialties, an India-based excipient manufacturer, inaugurated Tabcell, India's largest MCC manufacturing plant in Nagpur. Equipped with advanced technology and an installed capacity of 1,200 metric tons, the plant was inaugurated by Union Minister Nitin Gadkari and represents a key milestone under the Government of India's Production Linked Incentive (PLI) scheme for excipients. This facility enhances Nitika Pharma's position as a global leader in pharmaceutical excipients, serving both domestic demand and exports to over 92 countries, while also supporting the "Make in India" initiative and generating significant local employment opportunities.
In December 2024, Nordic Bioproducts Group, a Finland-based manufacturer of MCC, partnered with C.Q. Masso to expand the supply of sustainable microcrystalline cellulose for the beauty and personal care sector. This collaboration aims to help manufacturers meet evolving EU regulations on harmful ingredients and product traceability by providing MCC, a renewable, wood-derived alternative to materials such as talc and titanium dioxide. The partnership supports the industry's shift toward safer, environmentally responsible formulations while ensuring a reliable and traceable supply chain across Europe. C.Q. Masso is a Spain-based company that produces chemical specialties across multiple sectors.
Major companies operating in the pharma grade cellulose powder market are Roquette Freres, Ashland Global, JRS Pharma, DFE Pharma, Sigachi Industries Ltd., Accent Microcell Ltd., FMC Corporation, Dow Chemical Company, Shin-Etsu Chemical Co. Ltd., Colorcon, Nippon Paper Industries Co. Ltd., Rayonier Advanced Materials, Lotte Fine Chemical, Mingtai Chemical Co. Ltd., Weifang Lude Chemical Co. Ltd., Shandong Head Co. Ltd., Zhejiang Kehong Chemical Co. Ltd., Anhui Sunhere Pharmaceutical Excipients Co. Ltd., Maple Biotech Pvt. Ltd., Ankit Pulps & Boards Pvt. Ltd.
North America was the largest region in the pharma-grade cellulose powder market in 2025. The regions covered in the pharma grade cellulose powder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pharma grade cellulose powder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pharma-grade cellulose powder market consists of sales of sodium carboxymethyl cellulose and cellulose acetate phthalate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharma Grade Cellulose Powder Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pharma grade cellulose powder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pharma grade cellulose powder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharma grade cellulose powder market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.